IQVIA announced a transformative collaboration with NRx Pharmaceuticals. IQVIA to collaborate with NRx as its designated partner, to provide pharmacovigilance services and medical information in preparation for potential regulatory actions. This collaboration will allow NRx to access IQVIA's domain experience with COVID-19, its unparalleled data assets, and analytics to support potential emergency use authorization (EUA) of ZYESAMI.

IQVIA will work closely with NRx to support key activities required for EUA activation, including the pharmacovigilance and medical information programs.